In addition to PD-L1 staining, metrics such as the Immunoscore that assesses CD3/CD8+ tumor-infiltrating lymphocytes [101,102] could improve the identification of patients who are more likely to respond to immunotherapeutics. This evidence concerns the gene CD274 and neoplasm.